获取途径

作者

刘保成 杨清锐 麻贞贞 刘东霞

作者单位

山东第一医科大学附属省立医院风湿免疫科，山东 济南

刊名

Advances in Clinical Medicine

年份

2024

卷号

Vol.14 No.2

页码

2814-2820

ISSN

2161-8712

关键词

托珠单抗 肺间质病变 类风湿关节炎 系统性硬化症 系统性红斑狼疮 Tocilizumab Interstitial Lung Disease Rheumatoid Arthritis Systemic Sclerosis Systemic Lupus Erythematosus

摘要

Connective-Tissue Disease often affects various organs throughout the body. Various CTDs such as Rheumatoid Arthritis , Systemic Sclerosis , Systemic Lupus Erythematosus and other diseases can easily affect the lungs, seriously affect respiratory function, and have a high fatality rate. At present, immunosuppressants, supportive treatments, anti-fibrosis treatments and antioxidant treatments are the main clinical treatments. However, there are no clear guidelines for the duration of use, maint...更多

Connective-Tissue Disease often affects various organs throughout the body. Various CTDs such as Rheumatoid Arthritis , Systemic Sclerosis , Systemic Lupus Erythematosus and other diseases can easily affect the lungs, seriously affect respiratory function, and have a high fatality rate. At present, immunosuppressants, supportive treatments, anti-fibrosis treatments and antioxidant treatments are the main clinical treatments. However, there are no clear guidelines for the duration of use, maintenance and reduction standards, and some patients have poor efficacy. In recent years, the interleukin-6 receptor antagonist tocilizumab has begun to be ap-plied to a variety of CTD-ILD patients, but its treatment options and duration of use have yet to be explored. This article will review the existing literature at home and abroad based on clinical guide-lines and disciplinary progress in recent years, summarize the research progress of TCZ in the use of common CTD-ILD, and provide reference for clinical practice.收起

文献类型

期刊